ABS-201

Last updated

ABS-201
Clinical data
Other namesABS201
Routes of
administration 		Subcutaneous injection [1]
Drug class Prolactin receptor monoclonal antibody
ATC code
  • None

ABS-201 is a monoclonal antibody against the prolactin receptor (PRLR) which is under development for the treatment of androgenic alopecia (hair loss) and endometriosis. [1] [2] [3] [4] It is taken by long-lasting subcutaneous injection. [1] [3]

Contents

The drug is claimed to work by activating dormant hair follicles and causing them to move from the telogen phase to the anagen phase. [3] [4] ABS-201 has been found to produce robust hair regrowth in mice and balding macaques that was greater than that with minoxidil. [3] [4] It might also be able to reverse greying of hair. [3]

ABS-201 is under development by AbSci. [1] [2] As of October 2025, it is in the preclinical research stage of development for alopecia. [1] [3] A phase 1/2a clinical trial for alopecia is being planned for late 2025 or early 2026. [1] [3] The development of ABS-201 is being overseen by prominent hair loss researcher Rodney Sinclair. [3] The chemical structure of the drug does not yet appear to have been disclosed. [1]

See also

References

  1. 1 2 3 4 5 6 7 "ABS 201". AdisInsight. 7 October 2025. Retrieved 14 November 2025.
  2. 1 2 "Delving into the Latest Updates on ABS-201(Absci Corp) with Synapse". Synapse. 25 October 2025. Retrieved 14 November 2025.
  3. 1 2 3 4 5 6 7 8 Frederickson E (20 October 2025). "A New Hair Loss Drug Could Cure Balding and Reverse Graying". Popular Mechanics. Retrieved 14 November 2025.
  4. 1 2 3 Kahn A (2024). "Absci 2024 R&D Day Presentation". Absci Corporation.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.